142 related articles for article (PubMed ID: 21937923)
1. Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study.
Staehelin C; Keiser O; Calmy A; Weber R; Elzi L; Cavassini M; Schmid P; Bernasconi E; Furrer H;
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):79-85. PubMed ID: 21937923
[TBL] [Abstract][Full Text] [Related]
2. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.
Nellen JF; Wit FW; De Wolf F; Jurriaans S; Lange JM; Prins JM
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):943-50. PubMed ID: 15220701
[TBL] [Abstract][Full Text] [Related]
3. Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?
Gatey C; Brun A; Hamet G; Diamantis S; Sellier P; Bouchaud O; Garrait V; Rozenbaum W; Molina JM; Abgrall S;
HIV Med; 2019 Feb; 20(2):175-181. PubMed ID: 30506853
[TBL] [Abstract][Full Text] [Related]
4. Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.
de Monteynard LA; Dray-Spira R; de Truchis P; Grabar S; Launay O; Meynard JL; Khuong-Josses MA; Gilquin J; Rey D; Simon A; Pavie J; Mahamat A; Matheron S; Costagliola D; Abgrall S;
PLoS One; 2015; 10(3):e0118492. PubMed ID: 25734445
[TBL] [Abstract][Full Text] [Related]
5. Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study.
Thierfelder C; Weber R; Elzi L; Furrer H; Cavassini M; Calmy A; Bernasconi E; Gutmann C; Ledergerber B;
HIV Med; 2012 Feb; 13(2):118-26. PubMed ID: 22107170
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
[TBL] [Abstract][Full Text] [Related]
7. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study.
Weber R; Huber M; Battegay M; Stähelin C; Castro Batanjer E; Calmy A; Bregenzer A; Bernasconi E; Schoeni-Affolter F; Ledergerber B;
HIV Med; 2015 Mar; 16(3):137-51. PubMed ID: 25124393
[TBL] [Abstract][Full Text] [Related]
8. Country of birth does not influence long-term clinical, virologic, and immunological outcome of HIV-infected children living in the Netherlands: a cohort study comparing children born in the Netherlands with children born in Sub-Saharan Africa.
Cohen S; van Bilsen WP; Smit C; Fraaij PL; Warris A; Kuijpers TW; Geelen SP; Wolfs TF; Scherpbier HJ; van Rossum AM; Pajkrt D
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):178-85. PubMed ID: 25405830
[TBL] [Abstract][Full Text] [Related]
9. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
10. Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study.
Gebreselassie HM; Kraus D; Fux CA; Haubitz S; Scherrer A; Hatz C; Veit O; Stoeckle M; Fehr J; de Lucia S; Cavassini M; Bernasconi E; Schmid P; Furrer H; Staehelin C;
HIV Med; 2017 Sep; 18(8):564-572. PubMed ID: 28247589
[TBL] [Abstract][Full Text] [Related]
11. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival.
Staehelin C; Rickenbach M; Low N; Egger M; Ledergerber B; Hirschel B; D'Acremont V; Battegay M; Wagels T; Bernasconi E; Kopp C; Furrer H;
AIDS; 2003 Oct; 17(15):2237-44. PubMed ID: 14523281
[TBL] [Abstract][Full Text] [Related]
12. A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.
Benoit AC; Younger J; Beaver K; Jackson R; Loutfy M; Masching R; Nobis T; Nowgesic E; O'Brien-Teengs D; Whitebird W; Zoccole A; Hull M; Jaworsky D; Rachlis A; Rourke S; Burchell AN; Cooper C; Hogg R; Klein MB; Machouf N; Montaner J; Tsoukas C; Raboud J; ;
Antivir Ther; 2017; 22(4):325-335. PubMed ID: 27925609
[TBL] [Abstract][Full Text] [Related]
13. Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.
; Rohner E; Schmidlin K; Zwahlen M; Chakraborty R; Clifford G; Obel N; Grabar S; Verbon A; Noguera-Julian A; Collins IJ; Rojo P; Brockmeyer N; Campbell M; Chêne G; Prozesky H; Eley B; Stefan DC; Davidson A; Chimbetete C; Sawry S; Davies MA; Kariminia A; Vibol U; Sohn A; Egger M; Bohlius J
Clin Infect Dis; 2016 Nov; 63(9):1245-1253. PubMed ID: 27578823
[TBL] [Abstract][Full Text] [Related]
14. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.
Hughes RA; Sterne JA; Walsh J; Bansi L; Gilson R; Orkin C; Hill T; Ainsworth J; Anderson J; Gompels M; Dunn D; Johnson MA; Phillips AN; Pillay D; Leen C; Easterbrook P; Gazzard B; Fisher M; Sabin CA
HIV Med; 2011 Nov; 12(10):583-93. PubMed ID: 21569188
[TBL] [Abstract][Full Text] [Related]
15. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
[TBL] [Abstract][Full Text] [Related]
17. Effects of Antiretroviral Therapy on CD4+ Cell Count, HIV Viral Load and Death in a South African Cohort: A Modelling Study.
Shoko C; Chikobvu D; Bessong PO
Pak J Biol Sci; 2020 Mar; 23(4):542-551. PubMed ID: 32363840
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.
Napravnik S; Eron JJ; Sterling TR; Juday T; Uy J; Moore RD
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):574-80. PubMed ID: 23072322
[TBL] [Abstract][Full Text] [Related]
19. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
Scherrer AU; Ledergerber B; von Wyl V; Böni J; Yerly S; Klimkait T; Bürgisser P; Rauch A; Hirschel B; Cavassini M; Elzi L; Vernazza PL; Bernasconi E; Held L; Günthard HF;
Clin Infect Dis; 2011 Dec; 53(11):1143-52. PubMed ID: 21998284
[TBL] [Abstract][Full Text] [Related]
20. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?
Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
HIV Med; 2018 Jan; 19(1):42-48. PubMed ID: 28741837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
